Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
- Conditions
- Renal Cell CarcinomaUrothelial CarcinomaCastration-resistant Prostate Cancer
- Interventions
- Drug: DCC-2812
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 60
- Registration Number
- NCT06966024
A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST)
- First Posted Date
- 2024-10-08
- Last Posted Date
- 2025-04-16
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 120
- Registration Number
- NCT06630234
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸HonorHealth, Scottsdale, Arizona, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- First Posted Date
- 2024-10-01
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT06619561
- Locations
- 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸Ronald Regan UCLA Medical Center, Los Angeles, California, United States
🇺🇸AdventHealth Orlando, Orlando, Florida, United States
Study of DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
- Conditions
- Advanced Solid TumorRAF MutationRAS MutationNF1 MutationNon-Small Cell Lung CancerPancreatic Ductal AdenocarcinomaMelanomaBRAF Gene MutationCRAF Gene MutationCastration-Resistant Prostate Cancer (CRPC)
- Interventions
- First Posted Date
- 2024-03-01
- Last Posted Date
- 2025-05-23
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 140
- Registration Number
- NCT06287463
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸University of California San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
- First Posted Date
- 2023-07-24
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 94
- Registration Number
- NCT05957367
- Locations
- 🇺🇸
University of Southern California - Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Department of Medicine-Hematology/Oncology, Los Angeles, California, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
A Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib
- First Posted Date
- 2023-02-17
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 54
- Registration Number
- NCT05734105
- Locations
- 🇮🇹
U.O.C. Oncologia Medica, Palermo, Italy
🇰🇷Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
- Conditions
- Gastrointestinal Stromal Tumors
- Interventions
- First Posted Date
- 2021-10-18
- Last Posted Date
- 2022-01-05
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Registration Number
- NCT05080621
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
- Conditions
- Tenosynovial Giant Cell Tumor, DiffuseTenosynovial Giant Cell TumorPigmented Villonodular SynovitisTenosynovial Giant Cell Tumor, LocalizedGiant Cell Tumor of Tendon Sheath
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-09-28
- Last Posted Date
- 2025-02-24
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 123
- Registration Number
- NCT05059262
- Locations
- 🇪🇸
Hospital Universitario Vall d'Hebron, Barcelona, Spain
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
A Phase 1/2 Study of Inlexisertib (DCC-3116) in Patients With RAS/MAPK Pathway Mutant Solid Tumors
- Conditions
- Non-Small Cell Lung CancerAdvanced Solid TumorMetastatic Solid Tumor
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 144
- Registration Number
- NCT04892017
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Washington University Siteman Cancer Center, Saint Louis, Missouri, United States
🇺🇸Rutgers Cancer Institute, New Brunswick, New Jersey, United States
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients With Advanced GIST
- Conditions
- GIST - Gastrointestinal Stromal Tumor
- Interventions
- First Posted Date
- 2020-08-28
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Deciphera Pharmaceuticals, LLC
- Target Recruit Count
- 13
- Registration Number
- NCT04530981
- Locations
- 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸Sylvester Comprehensive Cancer Center, Miami, Florida, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States